Targeting the erythropoietin receptor on glioma cells reduces tumour growth

Experimental Cell Research

Volumn 317, Issue 16, 2011, Pages 2321-2332

  Pérès, Elodie A ^a   Valable, Samuel ^a   Guillamo, Jean Sébastien ^a,b   Marteau, Léna ^a   Bernaudin, Jean François ^c   Roussel, Simon ^a   Lechapt Zalcman, Emmanuèle ^a,b   Bernaudin, Myriam ^a   Petit, Edwige ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Brain; Erythropoietin; Erythropoietin receptor; Glioma; Tumours

Indexed keywords

ERYTHROPOIETIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GLIOMA CELL; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR GROWTH;

ANIMALIA;

EID: 80051796340     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.06.011     Document Type: Article

References (41)

1. Juul S.E., Yachnis A.T., Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 1998, 52:235-249.
2. Lacombe C., Da Silva J.L., Bruneval P., Fournier J.G., Wendling F., Casadevall N., Camilleri J.P., Bariety J., Varet B., Tambourin P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J. Clin. Invest. 1988, 81:620-623.
3. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., Noguchi C.T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3974-3978.
4. Masuda S., Nagao M., Takahata K., Konishi Y., Gallyas F.J., Tabira T., Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J. Biol. Chem. 1993, 268:11208-11216.
5. Chen Z., Warin R., Noguchi C.T. Erythropoietin and normal brain development: receptor expression determines multi-tissue response. Neurodegener. Dis. 2006, 3:68-75.
6. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur. J. Haematol. 2007, 78:183-205.
7. Hardee M.E., Arcasoy M.O., Blackwell K.L., Kirkpatrick J.P., Dewhirst M.W. Erythropoietin biology in cancer. Clin. Cancer Res. 2006, 12:332-339.
8. Arcasoy M.O., Jiang X., Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem. Biophys. Res. Commun. 2003, 307:999-1007.
9. Sinclair A., Todd M., Forsythe K., Knox S., Elliott S., Begley C. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007, 110:477-488.
10. Fandrey J. Erythropoietin receptors on tumor cells: what do they mean?. Oncologist 2008, 13(Suppl 3):16-20.
11. Szenajch J., Wcislo G., Jeong J., Szczylik C., Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim. Biophys. Acta 2010, 1806:82-95.
12. Yasuda Y., Musha T., Tanaka H., Fujita Y., Fujita H., Utsumi H., Matsuo T., Masuda S., Nagao M., Sasaki R., Nakamura Y. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br. J. Cancer 2001, 84:836-843.
13. Yasuda Y., Fujita Y., Matsuo T., Koinuma S., Hara S., Tazaki A., Onozaki M., Hashimoto M., Musha T., Ogawa K., Fujita H., Nakamura Y., et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003, 24:1021-1029.
14. Arcasoy M.O., Amin K., Karayal A.F., Chou S., Raleigh J.A., Varia M.A., Haroon Z.A. Functional significance of erythropoietin receptor expression in breast cancer. Lab. Invest. 2002, 82:911-918.
15. Jeong J., Hoxhaj G., Socha A.L., Sytkowski A.J., Feldman L. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol. Cancer Res. 2009, 7:1150-1157.
16. Paragh G., Kumar S.M., Rakosy Z., Choi S., Xu X., Acs G. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am. J. Pathol. 2009, 174:1504-1514.
17. Acs G., Zhang P.J., Rebbeck T.R., Acs P., Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95:969-981.
18. Saintigny P., Besse B., Callard P., Vergnaud A., Czernichow S., Colombat M., Girard P., Validire P., Breau J., Bernaudin J., Soria J. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin. Cancer Res. 2007, 13:4825-4831.
19. Arcasoy M.O., Amin K., Chou S., Haroon Z.A., Varia M., Raleigh J.A. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin. Cancer Res. 2005, 11:20-27.
20. Swift S., Ellison A.R., Kassner P., McCaffery I., Rossi J., Sinclair A.M., Begley C.G., Elliott S. Absence of functional EpoR expression in human tumor cell lines. Blood 2010, 115:4254-4263.
21. Mohyeldin A., Dalgard C.L., Lu H., Mcfate T., Tait A.S., Patel V.C., Wong K., Rushing E., Roy S., Acs G., Verma A. Survival and invasiveness of astrocytomas promoted by erythropoietin. J. Neurosurg. 2007, 106:338-350.
22. Bernaudin M., Bellail A., Marti H.H., Yvon A., Vivien D., Duchatelle I., Mackenzie E.T., Petit E. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000, 30:271-278.
23. Evans S., Koch C. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003, 195:1-16.
24. Cao Y., Lathia J.D., Eyler C.E., Wu Q., Li Z., Wang H., McLendon R.E., Hjelmeland A.B., Rich J.N. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer 2010, 1:50-61.
25. Sartelet H., Fabre M., Castaing M., Bosq J., Racu I., Lagonotte E., Scott V., Lecluse Y., Barette S., Michiels S., Vassal G. Expression of erythropoietin and its receptor in neuroblastomas. Cancer 2007, 110:1096-1106.
26. Yin D., Kawabata H., Tcherniamtchouk O., Huynh T., Black K.L., Koeffler H.P. Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. Int. J. Oncol. 2007, 31:1193-1198.
27. Hassouna I., Sperling S., Kim E., Schulz-Schaeffer W., Rave-Fränk M., Hasselblatt M., Jelkmann W., Giese A., Ehrenreich H. Erythropoietin augments survival of glioma cells after radiation and temozolomide. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:927-934.
28. Merchionne F., Dammacco F. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. Br. J. Haematol. 2009, 146:127-141.
29. Khankin E.V., Mutter W.P., Tamez H., Yuan H., Karumanchi S.A., Thadhani R. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS One 2010, 5:e9246.
30. Valable S., Eddi D., Constans J., Guillamo J., Bernaudin M., Roussel S., Petit E. MRI assessment of hemodynamic effects of an angiopoietin-2 overexpression on a brain tumor model. Neuro Oncol. 2009, 11:488-502.
31. Goldberg M.A., Glass G.A., Cunningham J.M., Bunn H.F. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7972-7976.
32. Gobert S., Duprez V., Lacombe C., Gisselbrecht S., Mayeux P. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur. J. Biochem. 1995, 234:75-83.
33. Nakamura Y., Takano H., Osawa M., Tomita T., Kim D.K., Kojima M., Motohashi T., Miyoshi S., Hiroyama T., Tokumoto Y., Nakauchi H. Impaired erythropoiesis in transgenic mice overexpressing a truncated erythropoietin receptor. Exp. Hematol. 1998, 26:1105-1110.
34. Cartenì G., Giannetta L., Ucci G., De Signoribus G., Vecchione A., Pinotti G., Puglisi F., Contillo A., Pezzella G., Orecchia S., Beccaglia P. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Support. Care Cancer 2007, 15:1057-1066.
35. Henke M., Laszig R., Rübe C., Schäfer U., Haase K., Schilcher B., Mose S., Beer K.T., Burger U., Dougherty C., Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
36. Crivellato E., Nico B., Vacca A., Djonov V., Presta M., Ribatti D. Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia 2004, 18:331-336.
37. Ahlqvist-Rastad J., Albertsson M., Bergh J., Birgegård G., Johansson P., Jonsson B., Kjellen E., Påhlman S., Zackrisson B., Osterborg A. Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations. Med. Oncol. 2007, 24:267-272.
38. Sharp F.R., Bernaudin M. HIF1 and oxygen sensing in the brain. Nat. Rev. Neurosci. 2004, 5:437-448.
39. Batra S., Perelman N., Luck L.R., Shimada H., Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab. Invest. 2003, 83:1477-1487.
40. Hardee M.E., Cao Y., Fu P., Jiang X., Zhao Y., Rabbani Z.N., Vujaskovic Z., Dewhirst M.W., Arcasoy M.O. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2007, 2:e549.
41. Ribatti D., Poliani P.L., Longo V., Mangieri D., Nico B., Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 2007, 50:636-641.